A Randomised, Double-Blind, Placebo-Controlled Study of a Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) of a FimH Antagonist, EB8018, in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2017
At a glance
- Drugs EB 8018 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; First in man
- Sponsors Enterome
- 27 Oct 2017 According to an Enterome media release, results from this trial will be presented at an upcoming medical congress.
- 27 Oct 2017 Status changed from recruiting to completed according to an Enterome media release.
- 05 Jan 2017 According to an Enterome media release, the company anticipates to report the results from this study later in 2017.